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seconds, control vs. 762 6 56 seconds, Schering 23390, P ,Renal hemodynamics in radiocontrast medium-induced renal
0.0001).dysfunction: A role for dopamine-1 receptors.
Conclusion. We conclude that selective DA-1 receptor stim-Background. Radiocontrast medium (RCM) administration
ulation protects against RCM-mediated decrements in renalinduces a transient increase in renal blood flow (RBF), followed
hemodynamics, independent of changes in baseline GFR andby a prolonged vasoconstriction. This vasoconstrictor phase in
RBF. Clinical trials are required to examine whether selectiveRBF is accompanied by a decrement in glomerular filtration
DA-1 receptor stimulation may have a role in prophylaxisrate (GFR). Nonselective dopamine (DA) receptor stimulation
against nephropathy development in high-risk patients under-is known to increase RBF and GFR. Clinical studies, however,
going procedures that require RCM.fail to demonstrate a renoprotective effect of DA following
RCM administration. This lack of renoprotection may relate
to nonspecific adrenergic stimulation by DA. The effect of
select DA-1 receptor stimulation on renal hemodynamics fol- Radiocontrast medium (RCM)-induced renal dysfunc-lowing RCM administration has not been evaluated.
tion is a frequent cause of morbidity in hospitalized pa-Methods. This study tests the hypothesis that selective DA-1
tients, frequently extending their hospital stay or de-receptor stimulation blunts the declines in RBF and GFR that
follow RCM injections, independent of changes in baseline laying a surgical procedure [1–4]. Over the last two
RBF and GFR. Experiments were performed in six anesthe- decades, many animal and clinical studies have examined
tized, volume-depleted dogs. RBF was measured by an electro- interventions that may prevent RCM-induced renal dys-magnetic flow probe around the renal artery and GFR by inulin
function [3–17]. All pharmacological interventions in an-clearance. After a 60-minute equilibration period, baseline val-
imal models of RCM nephropathy that act to block vaso-ues of RBF, GFR, and arterial pressure were determined. Two
separate intrarenal bolus injections of the ionic RCM Reno- constriction prevent reductions in renal blood flow
graffin were then given in the presence of saline infusion. After (RBF) and glomerular filtration rate (GFR) that follow
a 60-minute recovery period, intra-arterial infusions of either RCM injection [4, 10, 11]. However, studies with dopa-the selective DA-1 receptor agonist fenoldopam or the selec-
mine (DA) infusion have led to mixed results [4, 10, 11].tive DA-1 receptor antagonist Schering 23390 were started in
Nonspecific stimulation of DA receptors by DA is wellrandom order, and experiments were repeated.
Results. Neither agent significantly altered baseline values known to increase RBF and GFR [18, 19]. The renal
of arterial pressure, RBF, or GFR rate. Fenoldopam prevented outcomes with DA infusion, following RCM administra-
reductions in GFR (217 6 2 Dml/min, control vs. 2 6 1 Dml/ tion in humans, however, have not been consistent [15–min, fenoldopam, P , 0.001). Conversely, GFR was further
17, 19–20]. This may be related to many factors, includingreduced in the presence of Schering 23390 (215 6 2 Dml/
the nonspecific nature of DA at doses greater than 2min, control vs. 223 6 1 Dml/min, Schering 23390, P , 0.05).
Similarly, the maximal reduction in RBF was blunted with mg/kg to stimulate not only dopaminergic receptors
fenoldopam (271 6 12 Dml/min, control vs. 23 6 2 Dml/min, DA-1 and DA-2, but also a and b receptors [18, 19, 21].
fenoldopam, P , 0. 01), whereas Schering 23390 potentiated Earlier studies with a-receptor blockade demonstratedmaximal RBF reductions following the RCM injection (285 6
a blunting of RCM-induced declines in GFR and RBF11 Dml/min, control vs. 2119 6 14 Dml/min, Schering 23390,
[6]. Earlier studies with DA used doses of 3 to 4 mg/min.P , 0.05). The duration of recovery from vasoconstriction was
also prolonged in the presence of Schering 23390 (342 6 35 This would have resulted in an a-receptor stimulation
[18]. Whether stimulation of these aforementioned non-
dopaminergic receptors, such as a receptors or someKey words: fenoldapam, dopamine, renal failure, renal blood flow,
vasoconstriction. other factor(s), counteracts some of the possible protec-
tive effects of DA remains unclear.Received for publication December 10, 1998
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RBF and GFR. Although there is clear evidence that not to alter baseline RBF or systemic pressure [18]. Fol-
selective DA-1 receptor stimulation results in renal vaso- lowing a 60-minute period in which stabilization of RBF
dilation in humans, there are no data to support the occurred and performance of baseline inulin clearance
hypothesis that selective stimulation of the DA-1 recep- was obtained, an injection of 2 ml in the RCM for 10
tor prevents RCM-associated nephropathy, independent seconds, diatrizoate meglumine, and diatrizoate sodium
of increasing baseline RBF or GFR. This study tests (Renograffin; E.R. Squibb, New Brunswick, NJ, USA)
the hypothesis that pretreatment with a selective DA-1 was placed into the renal artery through the previously
receptor agonist in doses that do not significantly alter described curved needle. The subsequent changes in
baseline arterial pressure, RBF, or GFR prevents hyper- RBF were recorded on a strip recorder. In addition to
osmolar RCM-induced reductions of both RBF and GFR. clearance data obtained at the end of this initial one-
hour period, all clearance periods following radiocon-
trast-medium injections were obtained at 15-minuteMETHODS
intervals. The injection of hyperosmolar RCM was re-
Six adult mongrel dogs of either sex weighing 15 to peated in duplicate at 15-minute intervals, allowing for
20 kg were fed an 80 mEq/day of sodium, and they had return of RBF to baseline. Urine was collected during
a non–water-restricted diet for a period of one week
this period, as was a blood sample for inulin determina-
prior to the study. The animals were deprived of food and
tion. The blood samples were obtained at approximatelywater overnight. Animals were set up for experimental
seven to eight minutes into each collection period follow-procedures as previously described [10, 11]. A summary
ing the radiocontrast injection. The GFR values reportedof the experimental protocol is shown in Figure 1. Briefly,
in the results for each intervention period represent theanimals were anesthetized with intravenous sodium pen-
average of the two clearance periods. After the secondtobarbital (30 mg/kg), intubated, and ventilated by a
bolus of RCM injection, a recovery postcontrast periodfixed volume-positive pressure respirator on room air.
of 60 minutes was used to measure the changes in inulinThrough a flank incision, catheters were placed into the
clearance and RBF as well as to establish a stable base-femoral artery for blood pressure recording and blood
line (Fig. 1). During each of the baseline collection peri-sampling. The femoral vein was cannulated for inulin
ods, urine was collected for two 30-minute periods andinfusion and the left ureter for urine sampling. Inulin
averaged for the baseline value preceding each radiocon-(12.5 g/liter) diluted in isotonic saline was infused into
trast injection. Following this period, either an infusionthe femoral vein at a rate of 1 ml/min and was continued
of the DA-1 receptor agonist fenoldopam or the DA-1throughout the experiment. GFR was determined by
receptor antagonist Schering 23390 was started by meansinulin clearance according to the formula (U/P)in 3 V,
of a Harvard pump. After an equilibration period of 60where (U/P)in is the ratio of urine plasma inulin concen-
minutes, the studies were repeated in the manner alreadytration and V is urinary flow rate. Inulin concentration
presented. A variation among the dog kidney weightswas measured using a previously described Anthrone
was not detected.methodology [22].
A single kidney and renal artery were exposed and
Statistics
isolated through a retroperitoneal flank incision, and the
All results are reported as a mean 6 sd. Comparisonsdogs were placed in dorsal suspension. An electromag-
between control and either fenoldopam or Scheringnetic flow probe (Micro Instruments Inc., Los Angeles,
23390 were made through the use of the paired Student’sCA, USA) was then placed around the renal artery for
t-test. RBF and GFR values are reported as the meandetermination of RBF. At approximately one hour after
maximum change in both vasodilation and vasoconstric-completion of the instrumentation, one 20 gauge curve
tion. The data are expressed as delta to correct for theneedle with small holes drilled along the sides was in-
variation in baseline.serted into the renal artery distal to the flow probe in
a direction opposite the blood flow. This needle was
maintained patent by isotonic saline infusion at a rate RESULTS
of 1 ml/min. Additionally, the contralateral femoral ar-
Renal hemodynamicstery was cannulated, and a catheter was inserted to the
The renal and systemic hemodynamic effects of intra-level of the renal arteries. Through this line, either the
renal RCM administration in the presence and absenceDA-1 receptor agonist fenoldopam (0.01 mg/kg/min;
of a DA-1 agonist or antagonist are summarized in TableSmith, Kline & French, Philadelphia, PA, USA) or the
1. The effects of either a DA-1 agonist or antagonist onDA-1 receptor antagonist Schering 23390 (0.1 mg/kg/
mean arterial pressure are also summarized in Table 1.min; (Schering-Plough, Kenilworth, NJ, USA) were in-
Neither the DA-1 receptor agonist fenoldopam nor thefused by means of a Harvard pump. Doses of each agent
were selected based on previous studies in dogs shown DA-1 receptor antagonist Schering 23390 altered mito-
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Fig. 1. Illustrated protocol. *Inulin concentration in urine measured at these points, blood concentration measured at mid point in the time period.
**Inulin infusion started one hour prior to the start of the experiment. Postcontrast (PC) values for a given period were summated and the means
provided in the Results section.
Table 1. Renal and systemic hemodynamic effects of radiocontrast medium administration in the presence and absence of a dopamine-1
(DA-1) receptor agonist and antagonist in six adult dogs
Time period Baseline-C Postcontrast-C Baseline-F Postcontrast-F Baseline-R Postcontrast-R Baseline-S Postcontrast-S
MAP mm Hg 10362 102 63 101 63 10262 10363 10263 104 64 10463
GFR ml/min 3661 19 61a 3562 3762 3362 1862a 3263 1262a
RBF ml/min 168614a 97611a 184618 181615 179613 94610a 162614 7169a
Abbreviations are: MAP, mean arterial pressure; GFR, glomerular filtration rate; RBF, renal blood flow; C, control period; F, fenoldopam period; R, recovery
period; S, Schering 23390 period.
a P , 0.05 compared to the respective baseline value
gen-activated protein. Moreover, the administration of by 47.2 6 7% (P , 0.01) in the control group (Fig. 2).
RCM itself did not alter mitogen-activated protein. Conversely, fenoldopam increased GFR, and Schering
The baseline RBF did not significantly differ between 23390 further reduced GFR beyond control levels (Fig.
the control and interventional periods (Fig. 2). Fenolda- 2). Although variance existed in baseline GFRs between
pam significantly magnified the increase of vasodilation control and experimental groups, it was not statistically
that followed the RCM injection (26 6 9 Dml/min, con- significant (Table 1).
trol vs. 57 6 7 Dml/min, fenoldopam, P , 0.03). The
duration of the vasodilatory response was also increased
DISCUSSIONby fenoldopam (22 6 4 seconds, control vs. 45 6 8 sec-
The data from these studies clearly indicate that selec-onds, fenoldopam, P , 0.01). Moreover, fenoldopam
tive DA-1 receptor stimulation prevents RCM-inducedblunted the decrement in the maximal vasoconstrictor
declines in renal hemodynamics in volume-depletedresponse (271 6 12 Dml/min, control vs. 23 6 2 Dml/
dogs. The preservation of GFR by DA-1 receptor stimu-min, fenoldopam, P , 0.01). Additionally, the duration
lation following RCM injection was independent of base-of vasoconstriction was markedly shortened by fenoldo-
line increases in RBF and changes in mean arterialpam (Fig. 3).
pressure. Moreover, this study demonstrates that fenol-In contrast, selective DA-1 receptor blockade potenti-
dopam increases the period of vasodilation and elimi-ated reductions in RBF (Fig. 2). Moreover, the duration
nates vasoconstriction so that the RCM may be clearedof vasoconstriction was also prolonged during the recov-
much faster by the nephron. Taken together with dataery period when the DA-1 receptor antagonist was in-
from previous studies, this study further supports thefused (Fig. 3). It is noteworthy that repeat injections
concept that DA receptor stimulation protects againstof RCM yielded a reproducible decline in RBF in all
worsening renal function following an arterial injectiongroups.
of a high osmolar contrast material [16, 17, 19]. Although
Glomerular filtration rate we did not compare the two agents, we hypothesize that
the protective effect of fenoldopam may be more predict-The data are summarized in Table 1. An injection of
hyperosmolar RCM maximally reduced the mean GFR able than that of DA. This relates to the fact that fenoldo-
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Fig. 2. Percent change in renal blood flow
(B) and glomerular filtration rate (A) from
baseline. *P , 0.05 compared with control.
Although the aforementioned agents have been shown
to generally protect against renal dysfunction following
RCM injection in animals, these data are not as promis-
ing in human studies. In general, other than adequate
hydration and the possible exceptions of adenosine re-
ceptor antagonists, calcium antagonists, and DA recep-
tor stimulation with low-dose DA, none of these pharma-
cological interventions have shown an added clinical
benefit for the reducing the risk of RCM nephropathy
in high-risk patients [4, 8, 9, 13, 14, 16, 19]. Thus, clinical
trials are needed to confirm the validity of this hypoth-
esis.
Although fenoldopam has been extensively studied
Fig. 3. Duration of vasoconstriction. The duration of vasoconstriction
and known for its effects on lowering blood pressure inis defined as the time that renal blood flow fell below the baseline value
persons with hypertensive urgencies and emergencies, itsuntil it returns to baseline (#P , 0.01 vs. fenoldopam; *P , 0.01 vs.
control or recovery). effects on the prevention of renal dysfunction associated
with RCM administration have not been tested in hu-
mans [21]. This agent has very potent vasodilating effects.
After a two-hour infusion of 0.5 mg/kg/min in normoten-pam is devoid of a- and b-adrenoreceptor stimulation,
sive subjects, RBF increased by as much as 75% abovewhich is well known to occur with DA in concentrations
baseline [21]. Because fenoldopam selectively stimulatesinfused at greater than 2 mg/min [18].
tissues rich in DA-1 receptors while devoid of any effectA number of animal studies have evaluated a variety
on a, b, or DA II receptors, it can selectively dilateof pharmacological interventions in an attempt to block
vascular beds without setting up competitive environ-the renal hemodynamic effects of RCM administration
ments such as DA, where a receptors are also stimulated[4, 6, 10–12]. The goal of many of these studies was
[18, 21]. This selectivity affords this selective DA-1 re-not only to understand the pathophysiology of RCM
ceptor agonist the possibility of preventing vasoconstric-nephropathy, but to develop interventions that could
tion that follows RCM injection without altering bloodpossibly prevent RCM nephropathy in high-risk patients.
pressure, baseline RBF, or GFR at the doses used inThese animal studies included infusions of atrial natri-
this study.uretic peptide, endothelin receptor antagonists, adeno-
A possible limiting factor in many clinical trials thatsine receptor antagonists, calcium antagonists, furose-
have evaluated the effects of various pharmacologicalmide, mannitol, DA, as well as inhibitors of oxygen/
agents for prevention of RCM nephropathy is hypoten-hydroxyl radical scavengers. This animal study provides
animal data to further support the concept that selective sion. Fenoldapam has potent vasodilating effects, even
at low doses [18, 21]. In our study, however, a very lowDA-1 receptor stimulation may reduce the incidence of
RCM nephropathy in humans. dose of fenoldopam was deliberately selected to avoid
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